All In Biotech

NDA 205433 · Pulmoflow INC

Kitabis Pak

Tobramycin · Inhalation · Aminoglycoside Antibacterial

Last checked: Nov 20, 2026Latest source record: Apr 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Dec 2, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

50 Phase 3, 6 recruiting

FAERS reports

13,080

10,454 serious, 1,288 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 13, 2024.

TOBRAMYCIN INHALATION SOLUTION PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV 1 < 25% or > 75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )]. TOBRAMYCIN INHALATION SOLUTION PAK contains tobramycin, an aminoglycoside antibacterial drug indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa ( 1 ).

Mechanism: Tobramycin is an aminoglycoside antibacterial [see Microbiology ( 12.4 )].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 2, 2014 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
1 products under this application
  • KITABIS PAK · TOBRAMYCIN 300MG/5ML · SOLUTION, INHALATION · Prescription · TE AN

Clinical trials

Interventional ClinicalTrials.gov studies with "Tobramycin" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use988
  • pneumonia838
  • infective pulmonary exacerbation of cystic fibrosis710
  • dyspnoea708
  • drug ineffective696
  • acute kidney injury690
  • hospitalisation562
  • death509
  • infection508
  • cystic fibrosis495
  • cough494
  • condition aggravated461

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200480
200597
200676
2007124
200890
200999
2010101
2011207
2012188
2013164
2014272
2015444
2016513
2017592
20181,110
20191,724
20201,506
20211,081
20221,028
2023866
20241,063
2025933
2026722

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 791 on PubMed

Sponsor: Pulmoflow INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.